Buprenorfin Actavis: Uses, Dosage & Side Effects
A sublingual partial opioid agonist used in medication-assisted treatment for opioid use disorder (opioid dependence)
Buprenorfin Actavis contains the active ingredient buprenorphine, a partial opioid agonist prescribed for the treatment of opioid use disorder (opioid dependence). Used as a sublingual tablet that dissolves under the tongue, it is part of a comprehensive medication-assisted treatment (MAT) program that includes medical, psychological, and social support. Buprenorphine is included on the WHO Model List of Essential Medicines and is recommended by major international guidelines as a first-line treatment for opioid dependence. This medication requires a prescription and should only be used under medical supervision.
Quick Facts: Buprenorfin Actavis
Key Takeaways
- Buprenorphine is a first-line medication for the treatment of opioid use disorder, recommended by WHO, NICE, ASAM, and major international guidelines as part of medication-assisted treatment (MAT).
- The sublingual tablet must be placed under the tongue and allowed to dissolve completely (5-10 minutes); it must never be chewed, crushed, swallowed whole, or injected, as misuse can be fatal.
- Combining buprenorphine with benzodiazepines, alcohol, or other CNS depressants significantly increases the risk of fatal respiratory depression; these combinations should be avoided or carefully monitored.
- Treatment should never be stopped abruptly; your doctor will gradually taper the dose to avoid withdrawal symptoms such as sweating, anxiety, restlessness, and muscle aches.
- As a partial opioid agonist, buprenorphine has a ceiling effect on respiratory depression that provides a wider safety margin compared to full opioid agonists such as methadone, though overdose can still occur.
What Is Buprenorfin Actavis and What Is It Used For?
Buprenorfin Actavis contains the active substance buprenorphine, which belongs to a class of medications known as opioid partial agonists. It is used as part of medication-assisted treatment (MAT) for individuals who have been diagnosed with opioid use disorder, previously referred to as opioid dependence. The medication is specifically indicated for adults and adolescents over 15 years of age who have consented to treatment for their opioid dependence.
Opioid use disorder is a chronic medical condition characterized by a problematic pattern of opioid use that leads to clinically significant impairment or distress. It affects millions of people worldwide and is associated with substantial morbidity and mortality, including death from overdose. The World Health Organization (WHO) recognizes opioid dependence as a medical condition that requires evidence-based pharmacological treatment combined with psychosocial support.
Buprenorphine works by binding to the same receptors in the brain (mu-opioid receptors) that are activated by opioids such as heroin, morphine, oxycodone, and fentanyl. However, unlike these full agonists, buprenorphine is a partial agonist, meaning it activates these receptors to a lesser degree. This produces enough opioid effect to suppress withdrawal symptoms and reduce cravings without producing the intense euphoria associated with full opioid agonists. The partial agonist property also creates a "ceiling effect" for respiratory depression, which provides an important safety advantage.
The medication also has antagonist activity at kappa-opioid receptors, which may contribute to its antidepressant-like effects and could help address the dysphoria (persistent low mood) that many patients experience during recovery from opioid use disorder. Buprenorphine has high affinity for the mu-opioid receptor, meaning it binds very tightly and can displace other opioids from the receptor. This property is important therapeutically but also means that if taken too soon after using other opioids, it can precipitate withdrawal symptoms.
MAT with buprenorphine has been shown to significantly reduce illicit opioid use, decrease the risk of fatal overdose, lower the transmission of infectious diseases associated with injection drug use (such as HIV and hepatitis C), reduce criminal activity, and improve social functioning and quality of life. International guidelines from WHO, the National Institute for Health and Care Excellence (NICE), the American Society of Addiction Medicine (ASAM), and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) all recommend buprenorphine as a first-line treatment option for opioid dependence.
What Should You Know Before Taking Buprenorfin Actavis?
Contraindications
Buprenorfin Actavis must not be used in certain situations where the risks clearly outweigh any potential benefit. Understanding these contraindications is essential for patient safety. You must not use this medication in the following circumstances:
- Hypersensitivity: Known allergy to buprenorphine or any of the excipients in the formulation, including lactose monohydrate, sunset yellow FCF (E110), magnesium stearate, sodium citrate, povidone, citric acid, pregelatinized maize starch, crospovidone, or mannitol.
- Severe respiratory insufficiency: Significant breathing problems from any cause, as buprenorphine can further suppress respiratory drive.
- Severe hepatic impairment: Severely reduced liver function, as buprenorphine is extensively metabolized by the liver and accumulation could lead to dangerous levels.
- Acute alcohol intoxication or delirium tremens: The combination of alcohol and opioids can cause fatal respiratory depression, and delirium tremens represents a medical emergency that requires specific treatment.
Warnings and Precautions
Deaths have occurred due to respiratory depression when buprenorphine was misused or combined with central nervous system depressants such as alcohol, benzodiazepines, or other opioids. Never inject sublingual tablets. Never combine with alcohol, benzodiazepines, or other sedatives without medical supervision. Seek emergency medical help immediately if you experience slow, shallow, or difficult breathing.
Before starting treatment with Buprenorfin Actavis, inform your doctor if you have any of the following conditions, as your dose may need to be adjusted or additional monitoring may be required:
- Asthma or other respiratory conditions: Buprenorphine can suppress breathing, and patients with existing lung disease are at higher risk.
- Liver disease: Including hepatitis B or C infection. Liver damage has been reported with buprenorphine use, particularly with misuse. Your doctor may perform regular blood tests to monitor liver function.
- Low blood pressure (hypotension): Buprenorphine may cause orthostatic hypotension (sudden drop in blood pressure when standing), leading to dizziness or fainting.
- Recent head injury or brain disease: Buprenorphine can increase intracranial pressure and may mask neurological symptoms.
- Urinary retention: Difficulty urinating due to enlarged prostate (in men) or urethral stricture.
- Kidney disease: Dose adjustment may be needed as elimination of buprenorphine metabolites depends partly on renal function.
- Thyroid problems: Both hypothyroidism and hyperthyroidism can affect how the body responds to opioids.
- Adrenal insufficiency: Including Addison's disease. Opioids can worsen adrenal insufficiency.
- Depression or other psychiatric conditions: Particularly if treated with antidepressants, as the combination may increase the risk of serotonin syndrome.
Buprenorfin Actavis can cause sleep apnea (breathing pauses during sleep) and sleep-related hypoxemia (low blood oxygen levels). Symptoms include breathing pauses during sleep, waking at night due to breathlessness, difficulty staying asleep, or excessive daytime sleepiness. Contact your doctor if you or someone close to you observes these symptoms, as a dose reduction may be considered.
Misuse, Abuse, and Diversion
This medication can be sought by people who misuse prescription drugs and should be stored securely to prevent theft. Never give this medication to anyone else, as it can be fatal or cause serious harm to individuals for whom it has not been prescribed. Injecting sublingual tablets can cause severe harm, including withdrawal symptoms, infections, and potentially fatal complications.
Repeated use of opioids, including buprenorphine, can lead to physical dependence and tolerance. While buprenorphine is used therapeutically to treat opioid dependence, it is important to use it only as prescribed. Signs that may indicate problematic use include: needing to use the medication for longer than prescribed, needing higher doses than recommended, using the medication for reasons other than those prescribed (such as to feel calm or help sleep), making repeated unsuccessful attempts to stop or reduce use, and feeling unwell when the medication is stopped but better when it is resumed.
Pregnancy and Breastfeeding
If you are pregnant, think you may be pregnant, or are planning to become pregnant, discuss this with your doctor before using Buprenorfin Actavis. The decision to use buprenorphine during pregnancy should be made only when the potential benefits outweigh the possible risks. Untreated opioid use disorder during pregnancy carries significant risks for both mother and baby, including preterm birth, low birth weight, and fetal distress.
When buprenorphine is used during late pregnancy, the newborn may experience neonatal abstinence syndrome (NAS), which can include breathing difficulties, excessive crying, tremors, feeding difficulties, and other withdrawal symptoms. These symptoms may appear several days after birth and require monitoring and supportive care in a neonatal unit.
Buprenorphine passes into breast milk and may affect the nursing infant. Breastfeeding should be discontinued while using Buprenorfin Actavis. Discuss alternative feeding options with your healthcare provider.
Driving and Operating Machinery
Buprenorphine can cause drowsiness, dizziness, and impaired concentration, particularly during the initial weeks of treatment, when doses are being adjusted, or when combined with alcohol or sedative medications. Do not drive, operate machinery, or perform hazardous activities until you know how this medication affects you. You are personally responsible for assessing whether you are fit to drive or perform tasks requiring alertness.
How Does Buprenorfin Actavis Interact with Other Drugs?
Buprenorphine interacts with numerous other medications, and some of these interactions can be life-threatening. It is essential to inform your prescribing physician about all medications you are taking, including prescription drugs, over-the-counter medicines, herbal supplements, and any illicit substances. Below are the most important drug interactions to be aware of.
Major Interactions (Life-Threatening Risk)
The combination of buprenorphine with benzodiazepines (such as diazepam, alprazolam, lorazepam, clonazepam) or similar drugs significantly increases the risk of drowsiness, respiratory depression, coma, and death. This combination should only be used when no other treatment options are available, with the lowest possible doses and shortest treatment duration, under close medical monitoring.
| Drug / Drug Class | Risk | Clinical Significance |
|---|---|---|
| Benzodiazepines (diazepam, alprazolam, lorazepam, clonazepam) | Fatal respiratory depression, coma, death | Avoid combination; if unavoidable, use lowest dose and monitor closely |
| Alcohol | Severe respiratory depression, increased sedation, death | Absolutely contraindicated; do not consume any alcohol during treatment |
| Gabapentinoids (gabapentin, pregabalin) | Respiratory depression, hypotension, deep sedation, coma | Use with extreme caution; monitor respiratory function |
| Other opioids (methadone, morphine, fentanyl, codeine) | Precipitated withdrawal or enhanced CNS depression | Do not combine; buprenorphine can displace full agonists from receptors |
| Naltrexone | Severe, prolonged withdrawal symptoms | Naltrexone blocks buprenorphine effects; do not combine |
Moderate Interactions
| Drug / Drug Class | Effect | Recommendation |
|---|---|---|
| SSRIs/SNRIs (fluoxetine, sertraline, venlafaxin, duloxetine) | Risk of serotonin syndrome (agitation, hallucinations, rapid heartbeat, hyperthermia) | Use with caution; monitor for serotonin syndrome symptoms |
| Tricyclic antidepressants (amitriptyline, doxepin) | Increased sedation, serotonin syndrome risk | Monitor closely; lowest effective doses |
| MAOIs (moclobemide, tranylcypromine) | Enhanced opioid effects, serotonin syndrome | Avoid combination or use extreme caution |
| CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, nelfinavir) | Increased buprenorphine plasma levels | Monitor for increased effects; dose reduction may be needed |
| CYP3A4 inducers (carbamazepine, phenytoin, phenobarbital, rifampicin) | Decreased buprenorphine levels and effectiveness | Monitor for reduced efficacy; dose increase may be needed |
| Anticholinergic drugs (antihistamines, antipsychotics, anti-Parkinson drugs) | Increased anticholinergic side effects (dry mouth, constipation, urinary retention) | Monitor for anticholinergic burden |
| Sedating antihistamines (diphenhydramine, chlorphenamine) | Increased drowsiness and CNS depression | Avoid or use with caution; advise against driving |
| Clonidine | Prolonged effects of buprenorphine; enhanced sedation and hypotension | Monitor blood pressure and sedation levels |
To achieve the best possible benefit from your treatment, you must tell your doctor about all medications you are using, including alcohol, alcohol-containing medications, illicit drugs, and non-prescribed medications. This is crucial for your safety, as seemingly harmless over-the-counter products can interact with buprenorphine.
What Is the Correct Dosage of Buprenorfin Actavis?
How to Take Sublingual Tablets
Buprenorfin Actavis sublingual tablets must be used correctly for the medication to be effective. Place the tablet under your tongue (sublingual administration) and allow it to dissolve completely. This process typically takes 5 to 10 minutes. This is the only correct method of administration. The tablets must never be chewed, crushed, or swallowed whole, as this will significantly reduce their effectiveness and may trigger withdrawal symptoms. Do not eat or drink anything until the tablet has completely dissolved.
Adults
Induction Phase (Starting Treatment)
From short-acting opioids (heroin, morphine): The first dose should be taken when clear withdrawal symptoms appear, but no earlier than 6 hours after the last use of the short-acting opioid. Starting treatment too early can precipitate severe withdrawal.
Switching from methadone: The methadone dose should ideally be reduced to below 30 mg/day before starting buprenorphine. The first dose should be taken when clear withdrawal symptoms appear, but no earlier than 24 hours after the last methadone dose.
Initial dose: 2-4 mg on day 1. Your doctor will assess your response and may give additional doses on the same day if needed, typically not exceeding 8 mg total on the first day.
Dose Titration
During the first week, your doctor will gradually increase the dose based on your clinical response and withdrawal symptoms. The dose is typically increased in increments of 2-8 mg. The goal is to find the lowest effective dose that prevents withdrawal symptoms and cravings without causing excessive sedation.
Maintenance Phase
Usual maintenance dose: 8-24 mg daily, taken as a single dose once per day. The maximum recommended daily dose is 24 mg. Most patients stabilize on 8-16 mg daily. Your doctor will determine the optimal dose based on your individual response.
Children and Adolescents
Buprenorfin Actavis is not recommended for children and adolescents under 15 years of age due to insufficient data on safety and efficacy in this age group. For adolescents aged 15 and older, the same dosing guidelines as for adults generally apply, but treatment should be initiated and monitored by specialists experienced in the management of opioid dependence in adolescents.
Elderly Patients
Elderly patients may be more sensitive to the effects of buprenorphine, particularly respiratory depression. Follow your doctor's instructions carefully. Dose adjustments may be necessary based on individual response, liver function, and overall health status. Close monitoring is recommended during treatment initiation and dose changes.
Patients with Kidney or Liver Problems
If you have kidney problems, your dose may need to be adjusted as the elimination of buprenorphine metabolites depends partly on renal function. If you have moderate liver impairment, your doctor will start with a lower dose and adjust carefully. Buprenorfin Actavis must not be used if you have severe liver impairment.
Missed Dose
If you forget to take your dose of Buprenorfin Actavis, contact your doctor as soon as possible. Do not take a double dose to make up for a forgotten dose. Consistent daily dosing is important for maintaining stable blood levels and preventing withdrawal symptoms. If you are unsure what to do, contact your prescribing physician or pharmacist.
Overdose
If you or someone else has taken too much Buprenorfin Actavis, or if a child has accidentally swallowed the medication, contact emergency services immediately. An overdose of buprenorphine can cause severe, life-threatening breathing difficulties. Symptoms of overdose include extreme drowsiness, pinpoint pupils, slow or shallow breathing, nausea, vomiting, low blood pressure, and loss of consciousness. Keep the person awake and breathing if possible while waiting for emergency help.
What Are the Side Effects of Buprenorfin Actavis?
Like all medications, Buprenorfin Actavis can cause side effects, although not everybody gets them. Most side effects are mild to moderate and often improve as treatment continues. However, some side effects can be serious and require immediate medical attention.
Allergic reactions: sudden wheezing, difficulty breathing or swallowing, swelling of eyelids, face, tongue, lips, throat or hands, skin rash or itching (especially covering the whole body). Also seek immediate help for: severe tiredness with loss of appetite or yellowing of skin/eyes (signs of liver damage), or breathing that is slower or weaker than normal (respiratory depression).
Very Common
May affect more than 1 in 10 people
- Insomnia (difficulty sleeping)
- Headache
- Nausea
- Excessive sweating (hyperhidrosis)
- Withdrawal symptoms
- Pain
Common
May affect up to 1 in 10 people
- Bronchitis, infection, influenza, sore throat, runny nose
- Swollen lymph nodes
- Hypersensitivity reactions
- Decreased appetite
- Agitation, anxiety, depression, hostility, nervousness, paranoia, abnormal thinking
- Dizziness, increased muscle tone, migraine, tingling in hands and feet, drowsiness, fainting, tremor
- Watery eyes, abnormal pupil dilation
- Palpitations (awareness of heartbeat)
- Vasodilation (widening of blood vessels)
- Cough, shortness of breath, yawning, asthma
- Abdominal pain, constipation, diarrhea, dry mouth, indigestion, gastrointestinal disturbances, flatulence, dental disease, vomiting
- Skin rash, itching
- Joint pain, back pain, bone pain, muscle cramps, muscle pain, neck pain
- Painful menstruation
- General weakness, chest pain, chills, malaise, peripheral edema (swelling in arms and legs), fever
Frequency Not Known
Cannot be estimated from available data
- Drug dependence
- Hallucinations
- Speech disorders
- Miosis (constricted pupils)
- Low blood pressure (hypotension)
- Urticaria (hives)
- Painful or difficult urination
- Neonatal withdrawal syndrome
- Abnormal liver test results
- Dental caries (tooth decay)
Liver Damage
Cases of liver damage have been reported with buprenorphine use, particularly when the medication is misused (for example, by injection). This risk is also increased by co-existing conditions such as hepatitis B or C infection, chronic alcohol use, anorexia, or concurrent use of other hepatotoxic medications. Your doctor may perform regular blood tests to monitor your liver function throughout treatment. Inform your doctor immediately if you develop symptoms such as unexplained fatigue, loss of appetite, nausea, or yellowing of the skin or eyes.
Withdrawal Symptoms After Initial Dose
After the first dose of Buprenorfin Actavis, some patients may experience opioid withdrawal symptoms, particularly if the medication is started too soon after the last use of a full opioid agonist. These symptoms typically include sweating, anxiety, restlessness, muscle aches, abdominal cramps, nausea, and diarrhea. This is why your doctor will carefully assess your readiness before prescribing the first dose and will ensure that clear withdrawal symptoms are present before treatment initiation.
How Should You Store Buprenorfin Actavis?
Proper storage of Buprenorfin Actavis is essential for both maintaining medication effectiveness and preventing accidental exposure. This medication can cause serious harm or death if taken by someone for whom it has not been prescribed, particularly children.
Keep this medication in a secure location where other people, especially children, cannot access it. Accidental ingestion of buprenorphine by a child or by an adult for whom it was not prescribed can be fatal. If accidental ingestion occurs, contact emergency services immediately.
- Blister packs: Store at or below 25°C (77°F). Keep in the original packaging to protect from moisture.
- Bottles: Store at or below 30°C (86°F). Keep the bottle tightly closed to protect from moisture.
- Do not use after the expiry date printed on the packaging (after "EXP"). The expiry date refers to the last day of that month.
- Do not dispose of medications via wastewater or household waste. Return unused medication to your pharmacy for proper disposal to protect the environment.
What Does Buprenorfin Actavis Contain?
Active Substance
The active ingredient is buprenorphine (as buprenorphine hydrochloride). Each sublingual tablet contains either 2 mg or 8 mg of buprenorphine. Buprenorphine is a semi-synthetic opioid derived from thebaine, an alkaloid of the opium poppy. It acts as a partial agonist at mu-opioid receptors and an antagonist at kappa-opioid receptors.
Inactive Ingredients (Excipients)
The other ingredients are: magnesium stearate, sodium citrate, povidone, citric acid, pregelatinized maize starch, lactose monohydrate, crospovidone, mannitol, and sunset yellow FCF (E110).
Lactose: This medication contains lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medication.
Sunset yellow FCF (E110): This medication contains the colorant sunset yellow (E110), which may cause allergic reactions in sensitive individuals.
Sodium: This medication contains less than 1 mmol (23 mg) sodium per tablet, meaning it is essentially sodium-free.
Appearance and Pack Sizes
Buprenorfin Actavis 2 mg sublingual tablets are uncoated, light orange, oval (5 x 8 mm), biconvex tablets marked with "B" on one side. Buprenorfin Actavis 8 mg sublingual tablets are uncoated, light orange, oval (7.35 x 13.35 mm), biconvex tablets marked with "B" on one side.
Available in bottles, standard blister packs, and child-resistant blister packs containing 1, 7, 20, 24, 28, 48, or 50 sublingual tablets. Not all pack sizes may be marketed in all countries.
Frequently Asked Questions About Buprenorfin Actavis
Buprenorfin Actavis contains buprenorphine, a partial opioid agonist used as part of medication-assisted treatment (MAT) for opioid use disorder (opioid dependence). It helps reduce cravings and withdrawal symptoms, allowing patients to participate in comprehensive treatment programs that include medical, social, and psychological support. It is available as sublingual tablets in 2 mg and 8 mg strengths and is intended for adults and adolescents over 15 years of age.
Place the sublingual tablet under your tongue and allow it to dissolve completely, which typically takes 5 to 10 minutes. Do not chew, crush, or swallow the tablet whole, as this will significantly reduce its effectiveness and may trigger withdrawal symptoms. Do not eat or drink until the tablet has fully dissolved. The first dose should only be taken when withdrawal symptoms are clearly present: at least 6 hours after the last use of a short-acting opioid (like heroin) or 24 hours after the last use of a long-acting opioid (like methadone).
Combining buprenorphine with benzodiazepines (such as diazepam, alprazolam, or clonazepam) or other sedatives is extremely dangerous and can be fatal. This combination significantly increases the risk of severe respiratory depression (inability to breathe), profound sedation, coma, and death. If your doctor prescribes both medications simultaneously, the doses and duration should be carefully limited and you should be closely monitored. Never take benzodiazepines that have not been prescribed by a doctor who is aware of your buprenorphine treatment.
The most common side effects (affecting more than 1 in 10 people) include insomnia (difficulty sleeping), headache, nausea, excessive sweating, withdrawal symptoms, and pain. Common side effects (affecting up to 1 in 10 people) include anxiety, depression, drowsiness, dizziness, constipation, vomiting, skin rash, muscle aches, and joint pain. Most side effects are mild to moderate and often improve as treatment continues. Contact your doctor if side effects are severe, persistent, or concerning.
Buprenorphine should only be used during pregnancy if the potential benefits outweigh the risks, and only under close medical supervision. Untreated opioid use disorder during pregnancy carries significant risks including preterm birth and fetal distress. If buprenorphine is used during late pregnancy, the newborn may experience neonatal withdrawal syndrome (neonatal abstinence syndrome), which includes breathing difficulties, tremors, and feeding problems. Your doctor will decide on the most appropriate treatment approach. Breastfeeding should be discontinued during buprenorphine treatment as the drug passes into breast milk.
Stopping buprenorphine abruptly can cause withdrawal symptoms including sweating, anxiety, restlessness, muscle aches, insomnia, nausea, diarrhea, and drug cravings. Treatment should never be stopped suddenly without medical guidance. After a period of successful treatment, your doctor will gradually reduce (taper) the dose over time based on your individual response and clinical situation. This tapering process may take weeks to months. If you want to stop treatment, always discuss a safe tapering plan with your prescribing physician first.
References & Sources
All medical information on this page is based on peer-reviewed research and international clinical guidelines. The following sources were consulted:
- 1 World Health Organization (WHO). Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. Geneva: WHO; 2009.
- 2 European Medicines Agency (EMA). Buprenorphine Summary of Product Characteristics (SmPC). EMA; 2024.
- 3 National Institute for Health and Care Excellence (NICE). Technology Appraisal Guidance TA114: Methadone and Buprenorphine for the Management of Opioid Dependence. NICE; 2007 (updated 2022).
- 4 Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. J Addict Med. 2020;14(2S):1-91.
- 5 U.S. Food and Drug Administration (FDA). Buprenorphine Sublingual Tablets Prescribing Information. FDA; 2023.
- 6 Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;(2):CD002207.
- 7 Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther. 1994;55(5):569-580.
- 8 Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.
- 9 European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Drug Treatment Overview: Opioid Substitution Treatment. EMCDDA; 2024.
- 10 World Health Organization (WHO). Model List of Essential Medicines, 23rd List. Geneva: WHO; 2023.
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, consisting of licensed physicians specializing in addiction medicine, clinical pharmacology, and psychiatry.
Written by iMedic Medical Editorial Team with expertise in addiction medicine and clinical pharmacology. Content based on current international guidelines and peer-reviewed research.
Reviewed by iMedic Medical Review Board. All claims verified against WHO, EMA, FDA, NICE, and ASAM guidelines. Evidence level: 1A (systematic reviews and meta-analyses of RCTs).
All content on iMedic follows strict editorial standards: evidence-based medical information reviewed by qualified physicians, no commercial funding or pharmaceutical company sponsorship, full transparency regarding sources and methodology, and adherence to the GRADE evidence framework. For more information, see our Editorial Standards page.